Compare Motorola Solutions Inc (MSI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Neurocrine Biosciences Inc — how do they compare? Motorola Solutions Inc trades at $463.3 (market cap $76.62B), while Neurocrine Biosciences Inc trades at $155 (market cap $15.77B). The key difference: Motorola Solutions Inc is far larger — about 4.9× Neurocrine Biosciences Inc's market cap, and Motorola Solutions Inc pays a 1.05% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MSI | NBIX | |
|---|---|---|
Market Cap | $76.62B | $15.77B |
Sector | Technology | Health |
52-Week High | $491.24 | $185.50 |
52-Week Low | $363.83 | $123.10 |
Enterprise Value | $85.53B | $15.78B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $462.98, down 1.08% today, with strong technical support at $459 and bullish moving averages. The company shows robust fundamentals with Q2 2026 EPS beating expectations at $4.41 vs. $3.85, revenue growth to $11.68B in 2025, and a $2B share repurchase authorization announced September 2026. Recent acquisition of D-Fend Solutions for $1.5B expands counter-drone capabilities.
Outlook remains positive with 70.6% analyst buy ratings and $536.50 consensus price target, representing 16% upside. Risks include elevated valuation multiples (P/E 36.48) and significant capital expenditures driving negative cash flow. The stock offers growth potential through security technology expansion but faces execution risks from recent acquisitions and competitive pressures.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
